![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Catco Reinsurance Opportunities Fund Limited | LSE:CAT | London | Ordinary Share | BMG1961Q3242 | ORD USD0.00013716 (DI) |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 24.00 | 13.00 | 35.00 | 24.00 | 24.00 | 24.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Unit Inv Tr, Closed-end Mgmt | 6.33M | 5.44M | 3.6440 | 6.59 | 35.84M |
RNS Number:7670Q Cambridge Antibody Tech Group PLC 12 September 2000 For Further Information Contact: Cambridge Antibody Technology Tel: +44 (0) 1763 263233 Dr David Chiswell, CEO John Aston, Finance Director Rowena Gardner, Communications Manager HCC De Facto (Europe) Tel: +44 (0) 20 7496 3300 Nikul Odedra (trade) Sue Charles (city/financial) Oxford Glycosciences plc Michael Kranda, Chief Executive Officer Tel : +44(0)1235 543200 Worldwide Web: http//:www.orgs.com BMC Communications/The Trout Group (USA) Tel: 001 212 477 9007 Brad Miles, ext 17 (media) Jonathan Fassberg, ext.16 (investors) Financial Dynamics (Europe) Tel: +44 (0) 20 7831 3113 David Yates Sarah Mehanna OXFORD GLYCOSCIENCES AND CAMBRIDGE ANTIBODY TECHNOLOGY ANNOUNCE STRATEGIC COLLABORATION IN ANTIBODY MICROARRAYS Melbourn and Oxford UK... Cambridge Antibody Technology (LSE: CAT) and Oxford GlycoSciences plc (LSE: OGS) today announced the formation of a strategic research collaboration to develop "Protein Chip" technology for detection of proteins using antibody based microarrays. CAT and OGS will combine their respective world-leading technologies, to develop a new protein detection and screening technology based on antibody microarrays. OGS's human protein libraries and CAT's human antibody libraries will be analysed, paired proteins and antibodies selected and microarrays developed based on OGS's current protein microarray prototype format. The goal is to create a new generation of protein detection technology, with the speed, throughput and sensitivity to serve the development of research tools, diagnostics and novel therapeutics. Each party will fund its own research contribution. Michael Kranda, CEO of OGS said, "With the Human Genome map in hand the spotlight has shifted to proteins, proteomics and antibody technology. The CAT/OGS Protein Chip project will focus on combining our expertise to explore the next generation of high throughput proteomics technology. We see the field of analytical proteomics maturing similarly to genomics. OGS pioneered industrialised proteomics based on 2D gels and mass spectrometry, for discovery of human proteins. We currently have over 800 patent filings covering disease specific proteins, with the number growing. Our technology team has used our expertise in proteomics, micro-engineering and informatics, to develop the prototype of an antibody-based protein detection microarray. The alliance with CAT provides us access to their high throughput antibody technology to bring our prototype microarrays to an industrial scale for developing protein chips as screening and diagnostic tools. We are very pleased to link up with the acknowledged antibody technology expertise at CAT". David Chiswell, CEO of CAT, said: "Understanding the expression, processing, modification and activity of proteins is fundamental to the development of revolutionary diagnostics, prognostics and therapies for human disease management. We at CAT believe that antibody-based microarrays will be a core tool for unlocking this understanding. CAT's extensive pioneering work on high throughput antibody isolation, which has included the world's first fully automated, high throughput antibody selection and screening processes developed three years ago, makes CAT the partner of choice to develop Protein Chips. Teaming up with the world-leading proteomics expertise at Oxford GlycoSciences is CAT's first collaboration designed to help solve the technological and commercial challenges in developing Protein Chips and to unlock the strategic value in this new market." Notes to Editors: Cambridge Antibody Technology (LSE:CAT) * CAT is a UK biotechnology company using its proprietary technologies in fully human monoclonal antibodies for drug discovery and drug development. Based in Melbourn, 10 miles south of Cambridge, England, CAT currently employs around 180 people. * CAT is listed on the London Stock Exchange, having raised #41m in its IPO in March 1997. A Secondary Offering in March 2000 raised #93m.* * CAT has a world-leading platform technology for rapidly isolating fully human monoclonal antibodies using proprietary phage display systems. CAT has an extensive phage display antibody library, currently incorporating around 100 billion distinct antibodies. This library forms the basis for the company's strategy to develop a portfolio of clinical development programmes and for discovering new drug leads using functional genomics. Four fully human therapeutic antibodies developed by CAT are at various stages of clinical trials. * CAT has a number of license and collaborative agreements in place with pharmaceutical and biotechnology companies including: Eli Lilly, Pfizer, BASF Pharma, Genentech, ICOS Corporation, Genetics Institute, Wyeth-Ayerst, Human Genome Sciences, AstraZeneca and Pharmacia. Oxford GlycoSciences (LSE:OGT) * OGS is the world's leading proteomics based drug discovery and development company headquartered in Oxfordshire, UK, applying its proteomics technology to pharmaceutical research and development. OGS has proteomics collaborations with a number of major pharmaceutical companies, including programmes with Pfizer in Alzheimer's disease and atherosclerosis, with Merck in diabetes, and in respiratory disease with Bayer. OGS also has a proteomics programme with Pioneer Hi-Bred/DuPont. Furthermore, in a joint venture with the genomics company, Incyte Genomics Inc., OGS is building expression databases for licence to pharmaceutical companies, to which AstraZeneca became the first subscriber in 1999. * OGS has drug discovery programmes in oncology, inflammation, and infectious disease, and a growing clinical and pre-clinical pipeline. OGT 918 (Vivesca(tm)) is in late stage clinical trials for the treatment of glycolipid storage disease. Microarrays * A microarray is a chemically modified surface (chip) onto which a high density of probes have been precisely applied in an ordered manner. Protein Chip * A protein chip is a chemically modified surface onto which a high density of protein-based probes have been precisely applied in an ordered manner. Some important facts that could cause actual results to vary significantly from management's expectations noted in these forward looking statements include government approvals, intellectual property positions and costs. OGT 918 is an investigational drug and has not received approval for marketing in any country.
1 Year Catco Reinsurance Opport... Chart |
1 Month Catco Reinsurance Opport... Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions